THE PROGRESS STUDY (on-going study, enrolment completed)

PROGRESS is a randomized clinical trial aiming to test the efficacy of an algorithm of the duration of antimicrobial treatment based on serum procalcitonin in patients with sepsis on the development of resistant bowel microbiota and of infections by Clostriidium difficile.

Study title: “A randomized prospective clinical trial to assess the role of PROcalcitonin-Guided antimicrobial therapy to REduce long-term infectionS Sequelae”
ClinicalTrials.gov NCT03333304
EudraCT number 2017-002011-33
National Organization for Medicines Approval: IS-62/17
National Ethics Committee Approval: 62/17
Study phase: II
Study sites: 5 sites in Greece
Target of enrolment: 281 patients
Actual start month: October 2017
Anticipated end month: July 2019
Current enrolment state: COMPLETED (completion of follow-up pending)